Combination of EUTOS score and 3‐month BCR‐ABL transcript level identifies a group of good‐risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy
暂无分享,去创建一个
R. Fanin | E. Calistri | A. Ambrosetti | M. Medeot | M. Tiribelli | M. Bonifacio | E. Maino | G. Semenzato | G. Binotto | L. Scaffidi | M. Nabergoj